END7 campaign aims to combat seven major NTDs by 2020

NewsGuard 100/100 Score

Launched today, the END7 campaign is dedicated to eliminating seven major neglected tropical diseases (NTDs) as a public health threat to poor communities by the end of 2020. 

NTDs infect one in six people worldwide, including 500 million children, and carry a higher health burden than malaria and tuberculosis.

The effects of these diseases are devastating. NTDs cause blindness, massive swelling in appendages and limbs, severe malnutrition and anemia. They are a leading cause of pregnancy complications among women and are a key source of poverty by reducing school attendance among children and worker productivity for adults.

Treatment for NTDs is one of the most cost-effective health programs available today. Pills to treat the seven leading NTDs are donated by pharmaceutical companies and many programs use existing infrastructure, such as schools and community centers, to administer the treatments.

The END7 campaign raises the public awareness and funding required to cover the costs of distributing medicine and setting up treatment programs in impoverished communities. The annual cost works out to approximately 50 cents to treat and protect one person for a whole year against all seven diseases.

"I'm shocked by how much devastation these diseases cause. But what shocks me more is how simple the solution is. Pocket change to provide medicine that can help end not just one disease, but seven," said actor and campaign sponsor Bill Nighy, who lends his voice to the campaign's creative animated video.

The first comprehensive campaign to raise public awareness of all seven major NTDs, END7 is run by the Global Network for Neglected Tropical Diseases, an initiative of the Sabin Vaccine Institute.   "Unlike many global health campaigns, END7 has an end in sight," said Dr. Neeraj Mistry, Managing Director of the Global Network. "With enough support and donations we believe we can end the plight of people suffering from these diseases by the end of this decade."

END7 is a public/private partnership that seeks to catalyze grassroots support for NTD control efforts to encourage major political and philanthropic leaders to increase funding for this important global health issue. The UK and U.S. governments, as well as major pharmaceutical companies, have already made significant contributions. END7 works with global partners such as the World Health Organization and the Bill & Melinda Gates Foundation.

The campaign will be managed through a Facebook hub developed by Wunderman UK to promote campaign videos, photographs, success stories and other content —including a real-time donation ticker.  Wunderman's animated video, 'Our Mission in a Minute', describes END7's goals in an engaging way and is the current featured content on Facebook.

"This campaign is truly about how together, we can have a huge influence on eliminating NTDs as a public health threat in a very short time frame," said David Harris, Executive Creative Director at Wunderman UK. "By making social media the core of END7, millions of people connected by Facebook and Twitter have an amazing opportunity to help millions of others suffering from these diseases."

SOURCE Sabin Vaccine Institute

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows potential for universal flu vaccine with broad antibody response